TELA Bio (TELA) Price & Analysis

Compare

158 Followers

TELA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.86 - $3.26

Previous CloseN/A

Volume34.27K

Average Volume (3M)83.85K

Market Cap

$68.93M

Enterprise Value$94.93M

Total Cash (Recent Filing)$34.98M

Total Debt (Recent Filing)$41.90M

Price to Earnings (P/E)―

Beta0.54

Next Earnings

Nov 05, 2025

EPS Estimate

-0.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.22

Shares Outstanding39,616,440

10 Day Avg. Volume129,863

30 Day Avg. Volume83,851

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.38

Enterprise Value/Revenue1.26

Enterprise Value/Gross Profit1.87

Enterprise Value/Ebitda-2.73

Forecast

1Y Price Target

$6.50

Price Target Upside277.91% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Leadership And ManagementThe appointment of Jeff Blizard, who brings extensive leadership experience from Abiomed, is seen as a positive move for TELA's growth strategy.

Product InnovationNew products like inguinal hernia and Liquifix have been successful since their launch, providing TELA opportunities in high-volume procedures.

Bears Say

Financial PerformanceDespite controlling some costs, the operating loss was higher than anticipated, suggesting financial challenges.

Sales ChallengesThe departure of 11 of 69 high-performing territory managers led to a significant drop in sales.

TELA Bio News

Tela Bio reports Q2 EPS (22c), consensus (19c)

Reports Q2 revenue $20.2M, consensus $20.67M. “We are at a pivotal inflection point for TELA, having built an...

12d ago

TELA

Tela Bio backs FY25 revenue view $85M-$88M, consensus $86.05M

The company said, “Full year 2025 revenue is projected to range from $85.0 million to $88.0 million, representing...

12d ago

TELA

TELA Bio Reports Strong Q2 2025 Growth

Tela Bio, Inc. ( ($TELA) ) has released its Q2 earnings. Here is a breakdown of the information...

11d ago

TELA

TELA Bio Reports Strong Q2 2025 Financial Results

TELA Bio ( ($TELA) ) has provided an announcement. On August 11, 2025, TELA Bio reported its financial...

12d ago

TELA

TELA Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Tela Bio, Inc. (TELA) is scheduled to report 2nd quarter earnings on 08/11/2025, after the market closes. Regarding...

14d ago

TELA

Tela Bio announces European launch of OviTex Inguinal Reinforced Tissue Matrix

Tela Bio (TELA) announced the European launch of OviTex Inguinal Reinforced Tissue Matrix, the only reinforced tissue matrix...

3M ago

TELA

TELA Bio Announces Leadership Change with New President

TELA Bio ( ($TELA) ) has shared an announcement. On May 30, 2025, TELA Bio announced the resignation...

3M ago

TELA

Tela Bio appoints Jeffrey Blizard as president, effective immediately

TELA Bio (TELA) announced the appointment of Jeffrey Blizard as President of TELA Bio, effective immediately. Blizard has...

3M ago

JNJ

TELA

TELA Bio Approves Key Proposals at Annual Meeting

TELA Bio ( ($TELA) ) just unveiled an update. On May 28, 2025, TELA Bio, Inc. held its...

3M ago

TELA

TELA Bio’s Earnings Call: Growth Amid Challenges

Tela Bio, Inc. (($TELA)) has held its Q1 earnings call. Read on for the main highlights of the...

4M ago

TELA

TELA Bio Reports Strong Q1 2025 Revenue Growth

Tela Bio, Inc. ( ($TELA) ) has released its Q1 earnings. Here is a breakdown of the information...

4M ago

TELA

TELA Bio Reports Q1 2025 Revenue Growth Amid Losses

An update from TELA Bio ( ($TELA) ) is now available. On May 8, 2025, TELA Bio reported...

4M ago

TELA

Tela Bio announces U.S. launch of larger sizes of OviTex PRS

TELA Bio (TELA) announced the U.S. launch of larger sizes of OviTex PRS Reinforced Tissue Matrix, the only...

5M ago

TELA

TELA Bio’s Earnings Call: Challenges and Optimism for 2025

Tela Bio, Inc. (($TELA)) has held its Q4 earnings call. Read on for the main highlights of the...

5M ago

TELA

TELA FAQ

What was TELA Bio’s price range in the past 12 months?

TELA Bio lowest stock price was $0.86 and its highest was $3.26 in the past 12 months.

What is TELA Bio’s market cap?

TELA Bio’s market cap is $68.93M.

When is TELA Bio’s upcoming earnings report date?

TELA Bio’s upcoming earnings report date is Nov 05, 2025 which is in 74 days.

How were TELA Bio’s earnings last quarter?

TELA Bio released its earnings results on Aug 11, 2025. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.176 by -$0.044.

Is TELA Bio overvalued?

According to Wall Street analysts TELA Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does TELA Bio pay dividends?

TELA Bio does not currently pay dividends.

What is TELA Bio’s EPS estimate?

TELA Bio’s EPS estimate is -0.19.

How many shares outstanding does TELA Bio have?

TELA Bio has 39,616,440 shares outstanding.

What happened to TELA Bio’s price movement after its last earnings report?

TELA Bio reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.176. Following the earnings report the stock price went down -13.978%.

Which hedge fund is a major shareholder of TELA Bio?

Currently, no hedge funds are holding shares in TELA

TELA Bio Stock Smart Score

Underperform

Fundamentals

Return on Equity

-676.41%

Trailing 12-Months

Asset Growth

12.18%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

TELA Bio

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

TELA Bio (TELA) Earnings & Revenues

Historic Earnings Reports

TELA Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted significant revenue growth, particularly in the OviTex and LIQUIFIX portfolios, as well as successful expansion in the European market. However, the company still faces challenges with its net loss and slight increase in sales and marketing expenses. Overall, the positive achievements outweighed the challenges.View all TELA earnings summaries

TELA Stock 12 Month Forecast

Average Price Target

$6.50

▲(277.91% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","2":"$2","4":"$4","6":"$6","8":"$8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2,4,6,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.86,2.2553846153846155,2.6507692307692308,3.046153846153846,3.441538461538461,3.8369230769230764,4.2323076923076925,4.627692307692308,5.023076923076923,5.418461538461538,5.813846153846153,6.209230769230769,6.604615384615385,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.86,2.216923076923077,2.573846153846154,2.930769230769231,3.287692307692308,3.644615384615385,4.001538461538462,4.358461538461539,4.7153846153846155,5.072307692307692,5.429230769230769,5.786153846153846,6.143076923076923,{"y":6.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.86,2.1784615384615384,2.496923076923077,2.8153846153846156,3.1338461538461537,3.4523076923076923,3.770769230769231,4.0892307692307694,4.407692307692308,4.726153846153847,5.044615384615385,5.363076923076923,5.681538461538461,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.53,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.49,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.37,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.99,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.02,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.95,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.86,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >